Please ensure Javascript is enabled for purposes of website accessibility

Should Investors Be Worried About Editas' Share Decline?

By Brian Orelli, PhD and Keith Speights - Mar 6, 2021 at 10:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Short-term issues shouldn't affect long-term investors.

In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the recent downturn in Editas Medicine's (EDIT -4.53%) stock price and the biotech's change in management. The valuation is an issue in the short term, but the long-term prospects of the gene-editing company still look sound even with a new executive in the corner office.

Brian Orelli: Teresa asks if we could talk about the recent news on management changes, and then somebody else said should Editas be put in the penalty box as of late, the performance has been terrible, ticker there is EDIT. Any thoughts on Editas? We talked about it I think a couple of weeks ago, or maybe it was last week, I don't know, everything's blending together.

Keith Speights: Their CEO change was unexpected, at least to me. I don't think it's necessarily a bad change though. The person that they've brought in has been on the board for quite a while and definitely has solid expertise and knows Editas very well, so I don't think it's necessarily bad news there.

Should it be put in the penalty box? Look, I think Editas is the kind of stock that you need to have a long-term perspective with. It's going to be highly volatile over the short term. That volatility could be positive, it could be negative as we're seeing over the last few weeks, but over the long term, if you believe in the technology, the CRISPR technology that Editas has, the stock could be a big winner over the long term. This is not one to jump in and out of, you'll get burned. If you believe in the company's approach, then just hanging onto it for the long term. I wouldn't invest too great of your portfolio in a clinical-stage biotech like this, but I think it does have good opportunities over the long, say, next 10 years.

Orelli: That's really the timeframe you need to be looking, not one month. It's down 15% over the last month. Over the last three months, it's up 89.9%. [laughs]

Speights: Yeah, I was talking about the volatility. It goes both ways with the stock like Editas. It can be negative like we're seeing right now, but it can also be quite positive. But again, all of that's noise, really. I think the bigger thing is to look at that 10-year time horizon, and if it's successful, it's going to be really successful.

Orelli: Neither one of us work for the services that recommended Editas, but I doubt it's going to get put in the penalty box off of a one-month decline. I think you've got to be thinking long-term. If you bought at the top, definitely, I feel your pain, but just realize that you should be buying it for years in advance, so I don't think that you should be worried about the small decline right now.

Speights: For what it's worth, I did buy shares of Editas several years ago, two or three years ago. I rarely buy clinical stage biotechs, just very rarely. But I thought the technology was intriguing, took a very small position in it. I really don't pay attention to these up and down moves all that much. I'm just holding on and we'll see how their pipeline candidates fair over the next few years.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
EDIT
$12.45 (-4.53%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.